Susquehanna International Group
HOWL icon

Susquehanna International Group’s Werewolf Therapeutics HOWL Stock Holding History

Susquehanna International Group’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-27,700
Closed -$179K – 12536
2024
Q1 		$179K Buy
+27,700
New +$161K ﹤0.01% 10718

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's HOWL Position: Q1 2026 in Review

Susquehanna International Group sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 99,829 shares — an estimated $63.2K sold.

Susquehanna International Group first reported a position in HOWL in Q4 2021 and held it in 8 quarters. The position peaked at $1.14M in Q1 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Susquehanna International Group reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 99,829 Werewolf Therapeutics shares in Q1 2026, an estimated $63.2K.
  • Susquehanna International Group first reported a position in Werewolf Therapeutics in Q4 2021 and held it in 8 quarters.
  • Susquehanna International Group's Werewolf Therapeutics position peaked at $1.14M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.